Lymphoma Hub

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Julie Vose, University of Nebraska Medical Center, Omaha, US, discussing unmet needs in the treatment of MCL. 

Vose provides an overview of the current treatment landscape for patie...

During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal antibodies for the treatment of DLBCL.

This discussion also featured Gilles Salles, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.

Prior to the discussion, Nowakowski presented an overview of tafasitamab (Tafa)...

During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma.

This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.

Prior to the discussion, Salle...

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 (NCT04970901) trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

In this interview, Dr Alderuccio dis...

During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the EPCORE NHL-2 (NCT04663347) trial, which evaluated epcoritamab (epcor) in combination with rituximab, cyclophosphamide, ...

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the STARGLO trial o...

This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Marek Trněný, Charles University, Prague, CZ. We asked, How effective is epcoritamab + R-ICE in patients wi...

The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma. 

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the...

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focusing on the combination of tafasitamab ...

During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL.

In this interview, Luminari shares data from the phase III inMIND (NCT04680052) trial of patients with relapsed/refractory foll...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 

In this interview, Paolo Ghia shares data from Arm D of the phase III SEQU...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on the SYMPHONY 1 trial (NCT04224493).

First, Salles explains the rationale for using tazemetostat, an oral EZH2 inhibitor, with lenalidomide and rituximab in the phase Ib SYMPHONY 1 trial for patients with relapsed/refractory ...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).

Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, an...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma?

Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapies, allogeneic CAR T-cell platforms,...

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?

Bosch opens by outlining common BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, noting that comparable efficacy and activity rates can cause difficulty when determining the most appropriate treatment; however, safety prof...

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?

Pavlovsky outlines the progress made in the use of interim positron emission tomography (PET) to guide therapeutic decisions in the last decade, but also notes its limitations, before discussing the latest improvements in basal imaging methods. Pavlovsky...

Host...

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)? 

Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseli...